Accession Number: | 0001104659-23-023877 |
Date: | 2023-02-16 |
Issuer: | SUPERNUS PHARMACEUTICALS, INC. (SUPN) |
Original Submission Date: |
MOTTOLA FRANK
C/O SUPERNUS PHARMACEUTICALS, INC.
9715 KEY WEST AVENUE
ROCKVILLE, MD 20850
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2023-02-16 | M | 1,500 | a | $0.00 | 8,944 | direct | ||
COMMON STOCK | 2023-02-16 | F | 753 | d | $38.74 | 8,191 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
PERFORMANCE SHARE UNIT | 0.0 | 2023-02-16 | deemed execution date | M | 1,500 (d) | 2031-04-30 | common stock 1,500 | $0.00 | 0 | direct |
ID | footnote |
---|---|
f1 | shares of common stock received upon the settlement of certain performance share units granted to the reporting person on april 30, 2021. |
f2 | on april 30 2021, the reporting person was awarded performance share units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. |